Skip to main content

Past Webinars

Technical Assistance Webinar for NOT-RM-24-009

  • Webinar date and time: September 5, 2024, 4:00 - 5:00 PM ET
  • Webinar slides

Technical Assistance Webinar for NOT-RM-24-009

Frequently Asked Questions

What activities will this Notice support?

The objective of this Notice is to provide funds to support preparatory activities and engagement with a contract research organization (CRO) that will be performing the replication study. Preparatory activities and engagement may include preparing unique reagents, providing protocols, and answering experimental and/or analytical questions. 

The CRO will receive a separate pool of funds to conduct the replication activities. The funds provided through the Administrative Supplement Notice NOT-RM-24-009 are not for the originating lab to perform replication experiment(s) themselves.

Will my lab be responsible for performing the replication study? Will I need to identify a different lab that can perform the replication studies?

No. The CRO, identified and engaged by NIH, will perform the replication activities. This Notice is to provide support for the original labs to engage with the CRO and any necessary preparatory activities. 

Expand All to search section using Ctrl+F |
Additional NOT-RM-24-009 FAQs

1. I received an award in response to a Common Fund funding opportunity, but my award is administered by a different NIH Institute, Center, or Office (ICO). Can I apply for this opportunity?

Yes, you may apply for this opportunity if your award, which is supported by the Common Fund, is administered by a different NIH ICO.

2. I am a Common Fund awardee with a no-cost extension. Can I apply for this opportunity?

You may apply for this opportunity if the Common Fund-supported parent award is in an extension period (e.g., cost or no-cost extension). However, the extended parent award must be able to receive funds on September 1, 2024, and be active throughout the one-year supplement period.

3. How would a replication study benefit my research?

Independent replication can benefit researchers by:

  • Providing additional data that could be used to support eventual IND applications and/or commercialization,
  • Bolstering novel findings that may serve as the basis for future research projects,
  • Validating novel tools, technologies, and methods that may be used in a wide variety of biomedical research applications,
  • Saving time and money for labs that are considering launching a new project and would benefit from validation of foundational results before proceeding,
  • Allowing research teams to receive feedback from external users on how to make tools more interoperable and/or accessible,
  • Bolstering the entire scientific enterprise by ensuring validity of research results that may be used to support further research.

4. Can I propose a new study that is within the scope of the parent project? 

No. New studies are not allowed for this NOSI. It must be a replication of an already-completed experiment or validation of a technology.

5. Will NIH or the CRO publicly share my methods or the outcome of the replication study?

No, the methods and results of the replication studies conducted through this NOSI will not be made public without the consent of the principal investigator(s). The CRO will provide NIH with anonymized, aggregated data on the replicability of the selected studies. 

6. Will the outcomes of the replication studies impact my current award or future NIH funding?

No, NIH will not use information from these replication studies to make decision or take action on any current or future funding. The CRO will provide NIH with anonymized, aggregated data on the replicability of selected studies. 

7. Would an investigator who has a vested interest in the CRO (founder, partner, or other financial or advisory relationship) be considered to have a conflict of interest?

Yes, this would be considered a conflict of interest and the investigator may not work with that CRO on activities supported by this NOSI. They are still welcome to apply, and if selected, would be paired with a different CRO.

8. Can I propose a replication study involving non-human primates?

The current pilot of this initiative requires that proposed studies must be completed within the one-year budget period. Due to the complexity of non-human primate studies, they are not likely to be feasible within a one-year period. Applicants are encouraged to reach out to the Replication Initiative team at CF-Replication@od.nih.gov with any questions about the feasibility of their proposed studies within this one-year timeframe.

9. Can we propose to apply research methods from a study in one animal model in a different animal model? 

No, your proposal must be an exact replication of the original study.

Contract Research Organization Capabilities

Listed below are experimental capabilities that the Contract Research Organization(s) (CRO) can use when replicating studies as part of this initiative. This list is not necessarily exhaustive; if you are interested in proposing a project and would need a more specialized technique or a capability not listed here, please reach out to CF-Replication@od.nih.gov to discuss whether the CROs would have that capability. 

This list is subject to additions and changes, so it is recommended to check back frequently for any updates.

  • Culture systems
    • Human cell culture
    • Bacterial cell culture
    • 3D organoid culture
    • Stem cell culture
    • Ex vivo tissue culture
    • Yeast culture
    • Arabidopsis culture
  • Model systems
    • Mouse 
    • Drosophila
  • Sequencing/'omics
    • Bulk RNA sequencing
    • Single-cell RNA sequencing
    • Bulk genome sequencing
    • Single-cell genome sequencing
    • Metabolomics
    • Proteomics
    • ChIP-Seq
    • Chromatin conformation assay (ex. Hi-C)
  • Synthesis
    • RNA synthesis
    • DNA synthesis
    • Gene library synthesis
    • Protein synthesis
    • Polymer synthesis
  • Gene editing
    • Viral genetic editing
    • Human cell genetic editing
    • Bacterial genetic editing
    • CRISPR-based gene editing
    • Lentivirus-based gene editing
  • Imaging
    • Light microscopy
    • Fluorescence microscopy
    • 3D microscopy (ex. confocal)
    • Cryoelectron microscopy
    • FISH and/or other in situ genetic imaging
    • Expansion microscopy
    • Raman microscopy
    • Ultrasound
  • Computational
    • Machine learning
    • Structural modeling
    • Network analyses
    • Finite element modeling
    • Statistical and experimental design consultation
  • Spectroscopy/Spectrometry
    • Magnetic resonance spectroscopy 
    • Mass spectrometry
    • Tyramide signal amplification mass spectrometry
    • NMR
  • Other
    • 3D bioprinting
    • Optogenetics
    • Cellular engineering

This page last reviewed on September 17, 2024